

Time Table
Day 3, July 21 (Sat)

		7	8	9	10	11	12	13	14	15	16	17	18	19	
Kobe International Exhibition Hall	Room 1 (Portopia Hall)	South Building 1F													
	Room 2 (Convention Hall South)	Hall No.2 1F			IS7 8:30-10:30 Immunotherapy in lung cancer	SY22 10:30-12:30 Clinical Research Act		MeS-27 12:50-13:40 The New Treatment Option of Cancer Immunotherapy for Non-Small Cell Lung Cancer - Atezolizumab -		SY23 14:40-16:40 Countermeasures against side effects by immune checkpoint inhibitors		Closing Remarks			
	Room 3 (Hall A)	Hall No.1 2F			SY24 8:30-10:30 Acquired resistance to molecular targeted therapy and strategy for overcoming	SY25 10:30-12:30 Clinical development among rare cancer		MeS-28 12:50-13:40 The latest trends of adjuvant chemotherapy for colon cancer from UCA Collaboration and the international consensus.		ISY8 14:40-16:40 Clinical practice guidelines in Japan, Asia and the world					
	Room 4 (Hall B)	Hall No.1 2F			SY26 8:30-10:30 Today and tomorrow in the elderly cancer care	JSMO Guideline Committee Program Revised edition of guidelines for diagnosis and treatment of cancer of unknown primary 10:30-12:10		MeS-29 12:50-13:40 Management of Stage IV Gastric Cancer - Established Sequence and Novel Options		O3-1 14:40-15:52 Molecular Targeted Drugs					
	Room 5 (Conference Room 2A)	Hall No.2 2F	MoS-8 7:30-8:20 Systemic Therapy for HCC: Integrating New Data into Practice		Advanced Seminar for CRC (Japan Society of Clinical Trials and Research) 8:30-11:00	O3-2 11:00-12:12 Immunotherapy 5 (Others)		MeS-30 12:50-13:40 Treatment of cancer associated coagulopathy		O3-3 14:40-15:40 Geriatric Oncology					
	Room 14 (Conference Room 2B)	Hall No.2 2F						MeS-31 12:50-13:40 Is RCT the strongest evidence? Conflicts between evidence and practice							
	Room 6 (Conference Room 3A)	Hall No.2 3F	MoS-9 7:30-8:20 Challenge "BRAF" as the driver gene opens up the future through Melanoma to NSCLC		SY27 8:30-10:30 Therapeutic strategies for triple negative breast cancer	ISY9 10:30-12:30 New therapeutic strategies for lymphoid malignancies		MeS-32 12:50-13:40 Global Strategies for the Treatment of EGFR Mutation Positive Patient		SY28 14:40-16:40 Pancreatic cancer treatment in the future					
	Room 7 (Conference Room 3B)	Hall No.2 3F	MoS-10 7:30-8:20 Gene Panel to Whole Exome Sequence: Can we adapt this for cancer genomic testing?		O3-4 8:30-9:30 Musculoskeletal Tumor 1	O3-5 9:30-10:30 Musculoskeletal Tumor 2	O3-6 10:30-11:30 Team Medical Care 2	O3-7 11:30-12:30 Carcinoma of Primary Unknown/Others	MeS-33 12:50-13:40 Hodgkin Lymphoma						
Kobe Portopia Hotel	Room 8 (Kairaku)	Main Building B1F			JS5 8:30-10:30 Joint Symposium 5 (JAPMed/JSMO) The latest trend of Health Technology Assessment (HTA) in Japan and Optimal Clinical Use Guidelines		ISY10 11:00-12:30 Future perspectives of treatment for NSCLC		MeS-34 12:50-13:40 Second-Line Strategies in the Treatment of Metastatic Colorectal Cancer	O3-8 14:40-15:40 Lung cancer7 (EGFR Mutation-positive NSCLC 3, 3rd Generation EGFR-TKI)	O3-9 15:40-16:40 Lung cancer8 (EGFR Mutation-positive NSCLC 4, Biomarker 3)				
	Room 9 (Kairaku)	Main Building B1F			AOL 8:30-10:30 Current status and perspectives of medical oncology in Asia-Pacific region	SY29 10:30-12:30 Management of hereditary cancer		MeS-35 12:50-13:40 The role of OPDIVO in NSCLC (tentative)		SY30 14:40-16:40 Treatment of rare cancers: coalition and centralization					
Kobe International Conference Center	Room 10 (Main Hall)	1F		EL18 8:30-9:00 Recent treatments in biliary tract and pancreatic cancer	EL19 9:00-9:30 Systemic Chemotherapy for Advanced Gastric Carcinoma	EL20 9:30-10:00 Cancer precision medicine based on genome biomarkers	EL21 10:00-10:30 Current progress of chemotherapy for esophageal cancer	EL22 10:30-11:00 Statistical aspects and cornerstones for clinical trials	EL23 11:00-11:30 Chemotherapy for colorectal cancer: current status and future perspectives	SL3 11:30-12:30 Patient-Reported Outcomes in Oncology	MeS-36 12:50-13:40 Collaboration beyond specialty in lung cancer treatment - febrile neutropenia and oral care	EL24 14:40-15:10 Managements of oncologic emergency occurred in patients with advanced cancer	EL25 15:10-15:40 Management of Immune-Related Adverse Events	EL26 15:40-16:10 The role of the regional cancer care critical paths to establish a regional medical network	EL27 16:10-16:40 Evidence-based palliative medicine
	Room 11 (International Conference Room)	3F			MP3 8:30-10:30 Nurses' "must know" on genomic medicine and genetic counseling	JS6 10:30-12:30 Joint Symposium 6 (JSCN/JSMO) Perspective of Safe Handling of Cancer Chemotherapy Drugs in Japan		MeS-37 12:50-13:40 Pathophysiology and management of bone disease in multiple myeloma		MP4 14:40-16:40 Break down the medical staff outpatient barrier!					
	Room 12 (501)	5F	MoS-11 7:30-8:20 Gastroenteropancreatic neuroendocrine tumor ~ Delve into deeper! Seek for the optimal treatment strategy ~		O3-10 8:30-9:30 Pancreatic Cancer 1	O3-11 9:30-10:30 Pancreatic Cancer 2	O3-12 10:30-11:30 Lung Cancer 9 (Lung Cancer Associated with Interstitial Pneumonia)	O3-13 11:30-12:30 Diagnosis (Lung Cancer)	MeS-38 12:50-13:40 Tips for success in Precision medicine ~Pan-tumor approach & in-house preparation~		O3-14 14:40-15:40 Malignant Lymphoma 2				
	Room 13 (502)	5F	MoS-12 7:30-8:20 Risk management of Tumor lysis syndrome		O3-15 8:30-9:30 Colorectal Cancer 3	O3-16 9:30-10:30 Colorectal Cancer 4	O3-17 10:30-11:30 Colorectal Cancer 5	O3-18 11:30-12:30 Colorectal Cancer 6	MeS-39 12:50-13:40 Geriatric oncology and palliative care in the real small world		O3-19 14:40-15:40 Supportive Care 2 (Treatment-related Complications/Others 2)	O3-20 15:40-16:40 Supportive Care 3 (Gastrointestinal Toxicities/Others 3)			
	Room 15 (504+505)	5F			Medical Oncology Seminar Part 1 Symposium 9:00-10:30		Medical Oncology Seminar Part 2 Case Conference 10:50-12:30		MeS-40 12:50-13:40 Personalized Treatment of ER+/HER2- early Breast Cancer (tentative)		Medical Oncology Seminar Part 3 14:40-16:10				
	Patient Advocate Program (401+402)	4F			PAP 9:30-10:30 がん患者と家族のこころのケア		PAP 11:00-12:00 がんと暮らし ~仕事のこと、治療費のこと、支援制度のこと~		PAP 12:50-13:40 ランチセミナー: 臨床試験~ガイドラインができるまで~	PAP 14:00-14:50 その人らしさを支える緩和ケア					
Poster Area (Convention Hall North)	Hall No.2 1F		Poster Set-up 8:00-9:00	Poster Display					Poster Session 9:00-13:50	Poster removal 14:00-15:10					

Explanatory Notes

- AOL** =Asia Oceania Leaders' Symposium
- JS** =Joint Symposium
- ISY** =International Symposium
- SY** =Symposium
- EL** =Educational Lecture
- SL** =Special Lecture
- MoS** =Morning Seminar
- MeS** =Medical Seminar
- MP** =Medical Staff Program
- O** =Oral
- P** =Poster
- (n)** Simultaneous Interpretation (E&J)
- E** English Session
- Sponsored by Princess Takamatsu Cancer Research Fund